Richard E. Chaisson, MD

Role: 
Faculty
Professor
Chaisson headshot

Dr. Richard E. Chaisson is a professor of medicine at the Johns Hopkins University School of Medicine. He holds joint appointments in epidemiology and in international health, both in the Johns Hopkins Bloomberg School of Public Health. His area of clinical expertise is infectious diseases, particularly tuberculosis and HIV/AIDS.

Dr. Chaisson serves as the director of the Johns Hopkins University Center for Tuberculosis Research, the director and principal investigator of the Johns Hopkins Center for AIDS Research.

He received his B.S. and M.D. degrees from the University of Massachusetts. He was an intern, resident, fellow and assistant professor of medicine at the University of California, San Francisco, prior to moving to Johns Hopkins.

From 1988 to 1998 he was director of the Johns Hopkins AIDS Service, leading the inpatient Polk Service on Osler 8 and the outpatient Moore Clinic.  He was a pioneer in observational cohort studies of HIV and with his colleague Richard Moore co-founded the Johns Hopkins HIV Clinic cohort, a major contributor to the study of the outcomes of HIV disease and its treatment.  He founded the Center for TB Research which is the leading academic center for basic, clinical, applied, and epidemiologic investigations in TB and its control.

Dr. Chaisson has conducted multiple trials of treatments and strategies to treat, prevent, and control TB, TB/HIV co-infection, and HIV.  From 2002-2014 he led the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), a Gates Foundation-funded consortium that conducted population-level trials of TB control strategies in high-burden areas.  From 2011-2018 he was inaugural chair of the TB Transformative Science Group of the AIDS Clinical Trials Group, leading the development and implementation of a large portfolio of trials address TB treatment and preventive therapy.

Dr. Chaisson has been recognized with numerous honors, including election to the Association of American Professors in 2016, the Champions of TB Control Award from the U.S. Agency for International Development (USAID) in 2014 and the American Thoracic Society's World Lung Health Award in 2006.

1 to 3 HP

Post Date: 
2023-01-24
   |   
Protocol Title: A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) to Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The “One...

Population Pharmacokinetic Modeling and Simulation of Rifapentine Allow Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing

Post Date: 
2022-09-20
   |   
Countries: 
Publication: 
Antimicrobial Agents and Chemotherapy
ABSTRACT The Brief Rifapentine–Isoniazid Efficacy for TB Prevention/A5279 trial demonstrated a 1-month daily regimen of rifapentine and isoniazid was noninferior to 9 months of isoniazid alone for preventing TB in persons living with HIV (PLWH). Our objective was to evaluate rifapentine...

Pregnancy in Women with HIV in a Tuberculosis Preventive Therapy Trial

Post Date: 
2022-08-01
   |   
Countries: 
Publication: 
JAIDS
Background: Tuberculosis preventive therapy (TPT) is recommended for people with HIV infection, including during pregnancy. The effect of TPT exposure at conception and during pregnancy is poorly documented. Methods: We report pregnancy outcomes among South African women...

Once-Weekly Rifapentine and Isoniazid (3HP) Among Patients with HIV Taking Dolutegravir-based Antiretroviral Therapy: A Phase I/II Clinical Trial

Post Date: 
2020-06-01
Publication: 
The Lancet HIV
Background Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV. However, a small previous trial of such therapy with dolutegravir in healthy, HIV-...

Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort

Post Date: 
2019-10-21
Publication: 
Clinical Infectious Disease
Background Both pregnancy and human immunodeficiency virus (HIV) increase the risk of tuberculosis disease, which results in poor maternal, pregnancy, and infant outcomes. Isoniazid preventive therapy (IPT) reduces mortality among individuals living with HIV in high-burden settings but has recently...

Johns Hopkins Medicine-Led Consortium to Receive Up to $200 Million to Fight TB Globally

Post Date: 
2022-08-04
Chaisson headshot; USAID Awards Johns Hopkins Medicine, Partners, Up to $200 Million for Global TB R
To address the global burden of TB, an international collaboration led by Johns Hopkins Medicine has today been awarded up to $200 million in research funding over five years by USAID for the SMART4TB project.